A recent randomized control trial enrolled patients with coronavirus disease 2019 (COVID) and found that tcVNS significantly reduced the levels of inflammatory markers, specifically C-reactive protein (CRP) and procalcitonin (Czura et al., 2022; Tornero et al., 2022). This evidence concerns the gene CRP and COVID-19.